Sumitomo Pharma Co., Ltd. SMDPY

Set alert

13.50 USD 0.00 0.00%

At close · Oct 29

13.50 Day range 13.50

7.84 52-week range 24.40

More statistics

Chart tools

Interval

Chart is warming up

The five-day price history for SMDPY has not been loaded yet. Try again in a moment.

News

2 months ago businesswire.com

Sumitomo Pharma America Announces First Patient Receives Treatment in Phase 1/2a Study for its Investigational Therapy DSP-3077 for Retinitis Pigmentosa

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sumitomo Pharma America, Inc. (SMPA) today announced that the first patient in its study evaluating DSP-3077 in the treatment of non-syndromic retinitis…
4 months ago businesswire.com

Sumitomo Pharma America Achieves Key Patient Enrollment Milestone for Pivotal Phase 2 Study of Enzomenib in the Treatment of Relapsed/Refractory Acute Leukemia

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sumitomo Pharma America, Inc. (SMPA) today announced that it has enrolled the required number of participants in its pivotal Phase 2 monotherapy trial for…
8 months ago seekingalpha.com

Sumitomo Pharma Co., Ltd. (DNPUF) Discusses R&D Progress, Oncology Pipeline, and Advances in Regenerative Medicine and Vaccines Transcript

Sumitomo Pharma Co., Ltd. (DNPUF) Discusses R&D Progress, Oncology Pipeline, and Advances in Regenerative Medicine and Vaccines Transcript
8 months ago cnbc.com

Sumitomo Pharma shares plunge 12% despite greenlight for Parkinson's treatment

Shares of Japan's Sumitomo Pharma fell over 12%. Japanese government endorsed the company's iPS cell-based therapy for Parkinson's and heart disease.